Skip to main content
Premium Trial:

Request an Annual Quote

Celera Genomics Revenues and Losses Fall in Q2 of 2004

NEW YORK, Jan. 28 (GenomeWeb News) - Celera Genomics reported decreased revenues and net losses for its fiscal year 2004 second quarter today, accompanied by smaller R&D spending.

 

For the quarter ended Dec. 31, 2003, Celera Genomics, a unit of Applera, reported revenues of $19.2 million, compared to $22.9 million for the same period a year ago.

 

The company's net loss for the quarter totaled $13.6 million, or $0.19 per share, compared to $16.1 million, or $0.23 per share, in the prior year quarter.

 

Celera spent $25.2 million for R&D during the quarter, compared to $32.9 million the year before.

 

As of Dec. 31, 2003, Celera had cash and short term investments of about $770 milllion.

 

 

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.